H.R. 9774

H.R. 9774: To amend the Federal Food, Drug, and Cosmetic Act to provide for expedited approval of priority nonprescription drugs, and for other purposes.

Introduced Robert Latta (R) HOUSE_BILL — 119th Congress
Plain English Summary

H.R. 9774 aims to amend the Federal Food, Drug, and Cosmetic Act to create a process for the expedited approval of certain nonprescription drugs that are considered a priority. This would potentially allow these drugs to reach the market more quickly, improving access for consumers.

Positive Media Summary

Some media outlets have praised H.R. 9774 for its potential to streamline the approval process for nonprescription drugs, highlighting that faster access to essential medications could benefit public health, especially in times of urgent need or during health crises.

Negative Media Summary

Critics in the media have expressed concerns that H.R. 9774 may compromise safety and efficacy standards by rushing the approval process for nonprescription drugs. There are fears that this could lead to inadequate testing and oversight, potentially putting consumers at risk.

Conflict of Interest Analysis Deep Analysis
2/10
Risk Level
Low
Total Donations
$0
PAC Percentage
0%
Policy Area
Health

The analysis of H.R. 9774, which aims to expedite the approval of priority nonprescription drugs, reveals no direct industry overlaps between the sponsor Robert Latta's top donor industries and the bill's subject matter. The top donor industries do not include pharmaceutical or healthcare sectors that would typically be directly impacted by expedited drug approval legislation. While there is significant lobbying activity in the healthcare space, particularly from the American Dental Association with $1,100,000, it does not directly correlate with the bill's focus on nonprescription drugs. Therefore, the potential for conflicts of interest appears minimal, as the financial interests of Latta's donors do not seem to align with the provisions of the bill.

Lobbying Activity — Who's Pushing?

Organizations that lobbied on issues related to this bill's policy area.

Client Lobbying Firm Amount
AMERICAN DENTAL ASSOCIATION AMERICAN DENTAL ASSOCIATION $1,100,000
CELLEBRITE INC. CELLEBRITE INC. $70,000
ANIMAL HEALTH INSTITUTE ANIMAL HEALTH INSTITUTE $55,000
SAFE KIDS WORLDWIDE SAFE KIDS WORLDWIDE $25,000
AMERICAN CONCRETE PIPE ASSOCIATION EDMUND GRABER $20,000
MATERIALS RESEARCH SOCIETY HILLSTAFFER, LLC $15,000
NAFA FLEET MANAGEMENT ASSOCIATION HILLSTAFFER, LLC $15,000
BETTENDORF IA EDMUND GRABER $10,000
NATIONAL UTILITY CONTRACTORS ASSN EDMUND GRABER $10,000
ILLINOIS PUBLIC TRANSIT ASSN EDMUND GRABER $10,000
NATIONAL COOPERATIVE BUSINESS ASSOCIATION NATIONAL COOPERATIVE BUSINESS ASSOCIATION undisclosed
FMC CORPORATION RED FLAG CONSULTING USA(FORMALLY KNOWN AS INTERNATIONAL BUSINESS-GOVERNMENT COUNSELLORS, INC) undisclosed
ASSOCIATION FOR DIPLOMATIC STUDIES AND TRAINING HILLSTAFFER, LLC undisclosed
NATIONAL ACADEMY OF NEUROPSYCHOLOGY HILLSTAFFER, LLC undisclosed
THE ETHYLENE OXIDE STERILIZATION ASSOCIATION, INC HILLSTAFFER, LLC undisclosed

Source: Senate Lobbying Disclosure Act (LDA) filings, 2026

Sponsor's Top Donor Industries

Top industries funding Robert Latta, ranked by total contributions.

Health Professionals $600,000,000
Individuals: $600,000,000 PACs: $0
Retired $187,500,000
Individuals: $187,500,000 PACs: $0

Source: OpenSecrets.org (Center for Responsive Politics)

TheBillRoom is free and independent. No ads, no subscriptions, no political funding. If this analysis was useful, reader support keeps it running.
Support Us